These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8432923)

  • 1. Hyperpigmentation and secondary hemochromatosis: a novel treatment with extracorporeal chelation.
    Held JL; Yankiver B; Kohn SR
    J Am Acad Dermatol; 1993 Feb; 28(2 Pt 1):253-4. PubMed ID: 8432923
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron chelation.
    Chandy M
    J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
    [No Abstract]   [Full Text] [Related]  

  • 3. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
    Lee JA; Tchantchaleishvili V; Vidula H
    Artif Organs; 2018 May; 42(5):575-576. PubMed ID: 29878536
    [No Abstract]   [Full Text] [Related]  

  • 5. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
    Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C
    Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversal of haemochromatotic cardiomyopathy in beta thalassaemia by chelation therapy.
    Politi A; Sticca M; Galli M
    Br Heart J; 1995 May; 73(5):486-7. PubMed ID: 7786668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis.
    Park SJ; Han CW
    J Korean Med Sci; 2008 Apr; 23(2):320-3. PubMed ID: 18437019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of secondary hemochromatosis.
    Gattermann N
    Dtsch Arztebl Int; 2009 Jul; 106(30):499-504, I. PubMed ID: 19727383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of iron overload with a disposable multi-day delivery system.
    Paolo C; Francesco S; Sergio A
    Am J Hematol; 1996 Jan; 51(1):95. PubMed ID: 8571948
    [No Abstract]   [Full Text] [Related]  

  • 10. Chelation therapy for iron overload.
    Nutr Rev; 1980 May; 38(5):185-7. PubMed ID: 7207885
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ; Spyrou A; Kolnagou A
    Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.
    Cooray SD; Heerasing NM; Selkrig LA; Subramaniam VN; Hamblin PS; McDonald CJ; McLean CA; McNamara E; Leet AS; Roberts SK
    J Med Case Rep; 2018 Jan; 12(1):18. PubMed ID: 29373985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term intraperitoneal deferoxamine for hemochromatosis.
    Swartz RD; Legault DJ
    Am J Med; 1996 Mar; 100(3):308-12. PubMed ID: 8629676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis].
    Giraud P; Orsini A; Giraud F; Pinsard N
    Arch Fr Pediatr; 1965 Apr; 22(4):463-8. PubMed ID: 5826583
    [No Abstract]   [Full Text] [Related]  

  • 15. Current status of iron chelation therapy with deferoxamine.
    Cohen A
    Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute iron intoxication: change in urine color during chelation therapy with deferoxamine.
    Fernández S; Castro P; Nogué S; Nicolás JM
    Intensive Care Med; 2014 Jan; 40(1):104. PubMed ID: 24072332
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hemochromatosis of the heart].
    Scieszka J; Kalina Z; Knap J
    Kardiol Pol; 1990; 33(11-2):71-6. PubMed ID: 2096256
    [No Abstract]   [Full Text] [Related]  

  • 18. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hemochromatosis and its modern treatment].
    Böttger G
    Z Gesamte Inn Med; 1967 Jun; 22(12):376-80. PubMed ID: 5593769
    [No Abstract]   [Full Text] [Related]  

  • 20. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.